Propanc Biopharma, Inc. Common Stock (NASDAQ:PPCB) — Market Cap & Net Worth
Market Cap & Net Worth: Propanc Biopharma, Inc. Common Stock (PPCB)
Propanc Biopharma, Inc. Common Stock (NASDAQ:PPCB) has a market capitalization of $2.30 Million ($2.30 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29824 globally and #6004 in its home market, demonstrating a -30.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Propanc Biopharma, Inc. Common Stock's stock price $1.01 by its total outstanding shares 2278371 (2.28 Million). See Propanc Biopharma, Inc. Common Stock capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Propanc Biopharma, Inc. Common Stock Market Cap History: 2026 to 2026
Propanc Biopharma, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $2.30 Million to $2.30 Million (0.00% CAGR).
Propanc Biopharma, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Propanc Biopharma, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PPCB by Market Capitalization
Companies near Propanc Biopharma, Inc. Common Stock in the global market cap rankings as of August 3, 2026.
Key companies related to Propanc Biopharma, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Propanc Biopharma, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Propanc Biopharma, Inc. Common Stock's market cap moved from $2.30 Million to $ 2.30 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.30 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Propanc Biopharma, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.30 Million USD |
| MoneyControl | $2.30 Million USD |
| MarketWatch | $2.30 Million USD |
| marketcap.company | $2.30 Million USD |
| Reuters | $2.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more